Dose-response Study of OPC-12759 Ophthalmic Suspension
NCT00234078
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
290
Enrollment
INDUSTRY
Sponsor class
Conditions
Dry Eye Syndromes
Interventions
DRUG:
0.5% OPC-12759
DRUG:
1% OPC-12759
DRUG:
2% OPC-12759
DRUG:
placebo
Sponsor
Otsuka Pharmaceutical Co., Ltd.